We Deliver!337-345-4500
Treatable Conditions

What conditions are treatable with medical marijuana in Louisiana?

As of August 1st, 2020, physicians can now recommend Medical Cannabis for ANY condition that they consider debilitating to their patient.

Louisiana law allows for ANY condition considered debilitating to an individual patient to be treated with medical marijuana. The list below shows some, but not all, common conditions that can often be effectively treated with medical marijuana. Click on each condition for additional information and links to scholarly articles. This list is not intended to be all inclusive.

Anxiety
  • Cannabis and anxiety: a critical review of the evidence
    – View Article
Insomnia
  • Cannabis, Cannabinoids, and Sleep: a Review of the Literature
    – View Article

 

Depression
  • Assessment of clinical outcomes of medicinal cannabis therapy for depression
    – View Article
Pain

Malignant Disease – Pain

  • Study – Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
    – M Darkovska-Serafimovska 2018 (1:1 Sativex) View Article

Chronic Pain

  • Systematic reviews on therapeutic efficacy and safety of Cannabis (including extracts and tinctures) for patients with multiple sclerosis, chronic neuropathic pain, dementia and Tourette syndrome, HIV/AIDS, and cancer receiving chemotherapy
    – L Amato 2017 (1:1 Sativex) View Article

Neuropathic Pain – MS

  • A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
    – RM Langford 2013 (1:1 Sativex) View Article
  • Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
    – D Rog 2007 (1:1 Sativex) View Article
  • Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
    – D Rog 2005 (1:1 Sativex) View Article

Non-cardiac Chest Pain

  • Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial
    – Z Malik 2016 (THC – Dronabinol) View Article

Chronic Spinal Cord Injury

  • Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons
    – K Ethans 2015 (THC – Dronabinol) View Article

Pancreatitis – Abdominal Pain

  • Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain
    – H Van Goor 2014 (THC – Namisol) View Article

Neuropathic Pain – MS

  • Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
    – S Schimrgk 2010 (THC – Dronabinol) View Article

Neurological Pain

  • A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
    – W Notcutt 2002 (THC – Marinol) View Article
Cancer

Cancer – Pain

  • Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain
    – A Lichtman 2018 (1:1 Sativex) View Article
  • Medical Marijuana Use in Oncology A Review
    – G Wilkie 2016 (1:1 Sativex) View Article
  • Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract & THC Extract in Patients w/Intractable Cancer-Related Pain
    – J Johnson 2010 (1:1 Oro-mucosal spray) View Article

Adv Cancer – Pain

  • An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
    – J Johnson 2013 (1:1 Sativex) View Article

Opiod-Refractory Cancer Pain

  • Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
    – RK Portenoy 2012 (1:1 Sativex) View Article

Cancer – Childhood Chemo Nausea Vomiting

  • Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood
    – R Phillips 2016 (THC – Cannabis) View Article 

Chemotherapy Induced Nausea

  • Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.
    – M May 2016 (THC-Dronabinol) View Article

Cancer – Nausea and Vomiting

  • Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
    – LA Smith 2015 (THC-Cannabis Exacts) View Article
  • Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system
    – KA Sharkey 2014 (THC-Dronabinol, 1:1 Sativex) View Article
  • Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
    – E Meiri 2007 (THC-Dronabinol) View Article
AIDS/ HIV

HIV/AIDS – Morbidity and Mortality

  • The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS.
    – EE Lutge 2013 (THC-Cannabis) View Article
Cachexia

  • Lung Cancer – Anorexia

    • The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial
      – JG Turcott 2018 (THC-Nabilone) View Article

    Anorexia and Weight Loss

    • Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer
      – M Badowski 2018 (THC-Dronabinol) View Article 

    HIV-Wasting Syndrome

    • A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
      – G Galetto 2008 (THC-Dronabinol Megestrol) View Article

    Cancer – Anorexia

    • Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
      – A Jatoi 2002 (THC-Dronabinol) View Article

Seizure Disorders

Many can experience relief from the following symptoms when treated with medical marijuana:

  • Nausea, vomiting or gastrointestinal discomfort
  • Sudden feelings of anxiety
  • Uncontrollable bodily movements, jerking or spasms
  • Headaches

Cannabis has anti-inflammatory and pain reduction properties that can help a patient during the recovery process after a seizure. Medical marijuana can also help to boost serotonin levels which fosters better emotional health.

Epilepsy

Epilepsy – Children

  • Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study
    – M Hausman-Kedem 2018 (20:1) View Article

Epilepsy

  • Epilepsy and Cannabis: A Literature Review
    – S Zaheer 2018 (CBD:THC and CBD) View Article
  • Cannabinoids and Epilepsy
    – EC Rosenberg 2015 (CBD) View Article
  • Epilepsy Cannabinoids for epilepsy
    – D Gloss 2014 (CBD) View Article

Epilepsy – Pediatric

  • CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience
    – M Tzadok 2016 (20:1) View Article
Multiple Sclerosis

MS

  • Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to
    multiple sclerosis
    – U Zetti 2016 (1:1 Oro-mucosal spray) View Article
  • Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
    – P Vermersch 2016 (1:1 Sativex) View Article
  • Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    – L Leocani 2015 (1:1 Sativex) View Article
  • Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    – O Fernandez 2014 (1:1 Sativex) View Article
  • A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
    – C Collin 2010 (1:1 Sativex) View Article
  • Randomized controlled trial of cannabis based medicine in spasticity caused by multiple sclerosis
    – C Collin 2007 (1:1 Oro- mucosal spray) View Article
  • Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
    – D Wade 2004 (1:1 Sativex) View Article

MS-Neurologic Disorders

  • Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
    – B Koppel 2014 (1:1 Sativex) View Article
Spasticity

Spasticity

  • Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol
    – D Boggs 2018 (1:1 Sativex) View Article

Chronic Spinal Cord Injury

  • Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience
    – C Grao-Castellote 2017 (1:1 Sativex) View Article

Spasticity – MS Induced

  • Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
    – U Zetti 2016 (1:1 Oro-mucosal spray) View Article
  • Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
    – P Vermersch 2016 (1:1 Sativex) View Article
  • Sativex® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    – L Leocani 2015 (1:1 Sativex) View Article
  • Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    – O Fernandez 2014 (1:1 Sativex) View Article
  • A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
    – C Collin 2010 (1:1 Sativex) View Article
  • Randomized controlled trial of cannabis based medicine in spasticity caused by multiple sclerosis
    – C Collin 2007 (1:1 Oro-mucosal CBM) View Article
  • Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
    – D Wade 2004 (1:1 Sativex) View Article

Chronic Spinal Cord Injury

  • Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons
    – K Ethans 2015 (THC-Dronabinol) View Article

Spasms – ALS

  • Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)
    – M Weber 2009 (THC-Dronabinol) View Article
Severe Muscle Spasms

Marijuana works by reducing inflammation, which can prevent muscle spasms. When medical cannabis is used, cannabinoid receptors in your ECS bind with THC and CBD, another cannabinoid. By binding to cannabinoid receptors, THC starts an anti-inflammatory response which prevents inflammation and muscle spasms.

Parkinson's Disease

MS, Autism, Parkinsons, Alzheimers, Tourette’s, Huntington’s, Epilepsy

  • Neurological Disorders in Medical Use of Cannabis: An Update
    – R Solimini 2017 (THC, CBD, plant) View Article

Parkinsons

  • The Therapeutic Potential of Cannabinoids for Movement Disorders
    – B Kluger 2015 (THC-Nabilone) View Article
  • Cannabis for dyskinesia in Parkinson disease A randomized double-blind crossover study
    – CB Carroll 2004 (Extract-Oral Cannabis) View Article
  • Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study
    – KA Sierdzan 2001 (THC-Nabilone) View Article

PD-Neurologic Disorders

  • Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
    – B Koppel 2014 (THC, plant) View Article
Glaucoma

Glaucoma

Retinal Hemodynamics

  • Dronabinol and retinal hemodynamics in humans
    – N Plange 2007 (THC-Dronabinol) View Article

Interocular Pressure

  • Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. [CBD shown to cause adverse events.]
    – I Tomida 2006 (Sublingual THC & CBD) View Article
PTSD

PTSD

  • Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention
    – M Zer-Aviv 2016 (THC-Nabilone) View Article
  • Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder
    – P Roitman 2014 (Oral THC) View Article

PTSD – Nightmares

  • The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study
    – R Jetly 2015 (THC-Nabilone) View Article

PTSD – Nightmares, Insomnia, Chronic Pain

  • Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder–Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications
    – C Cameron 2014 (THC-Nabilone) View Article
Autism Spectrum Disorder

Autism

  • Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study
    – A Aran 2018 (20:1) View Article
  • Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities
    – D Barchel 2018 (20:1) View Article
Crohn's Disease

Crohns

  • Cannabis finds its way into treatment of Crohn’s disease
    – R Schicho 2014 (THC, plant) View Article
  • Side effects, health risks, and a short duration of action limit the usefulness of this drug
    – T Naftali 2013 (THC) View Article
Muscular Dystrophy

Malignant Disease – Pain

  • Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
    – M Darkovska-Serafimovska 2018 (1:1 Sativex) View Article